SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
3 Biotechs That Could be Taken Out This Quarter
Drug Development
Why Drug Giants Like Merck & Co. and AstraZeneca PLC Scientists are Looking in the Toilet for New Cancer Treatments
June 14, 2017
 · 
2 min read
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
Deals
AstraZeneca PLC CEO Warns of More Setbacks, Admits Company is Still Vulnerable to a Takeover
June 12, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
SoCal’s Regulus Sinks After AstraZeneca PLC Bails on Lead NASH Drug
June 12, 2017
 · 
3 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Deals
AstraZeneca PLC Eases Its Migraine With $302 Million Sale
June 7, 2017
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Deals
Why Pfizer, AstraZeneca PLC and Clovis Oncology Aren’t Interested in Tesaro
June 2, 2017
 · 
3 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Business
AstraZeneca PLC Offloads Heart Drugs to Recordati in $300 Million Deal to Pump Up R&D
May 22, 2017
 · 
2 min read
Job Trends
AstraZeneca PLC Employees Can Now Work In Their Car
May 19, 2017
 · 
1 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Policy
AstraZeneca PLC Sues Former Exec After GlaxoSmithKline Poaches Him Away to Run Its Largest Business
May 16, 2017
 · 
2 min read
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
Drug Development
AstraZeneca PLC Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study
May 12, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More